Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 16,851 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 16,851 shares of the firm’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $9.11, for a total value of $153,512.61. Following the completion of the sale, the insider now owns 410,784 shares of the company’s stock, valued at $3,742,242.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock opened at $11.05 on Thursday. The company has a debt-to-equity ratio of 5.56, a quick ratio of 10.22 and a current ratio of 10.25. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $17.02. The stock’s fifty day moving average price is $8.43 and its 200-day moving average price is $8.83.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.12. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.93 million. During the same quarter last year, the firm earned ($1.33) EPS. On average, analysts expect that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, March 22nd.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Phathom Pharmaceuticals by 2.6% in the third quarter. Invesco Ltd. now owns 3,418,959 shares of the company’s stock valued at $35,455,000 after purchasing an additional 86,822 shares during the last quarter. Algert Global LLC purchased a new position in Phathom Pharmaceuticals in the third quarter valued at about $952,000. Principal Financial Group Inc. acquired a new stake in Phathom Pharmaceuticals in the second quarter worth about $151,000. Trexquant Investment LP boosted its holdings in Phathom Pharmaceuticals by 221.4% in the third quarter. Trexquant Investment LP now owns 58,825 shares of the company’s stock worth $610,000 after acquiring an additional 40,524 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Phathom Pharmaceuticals by 126.1% in the third quarter. GSA Capital Partners LLP now owns 121,892 shares of the company’s stock worth $1,264,000 after acquiring an additional 67,983 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.